drugset / Trial / NCT05527444
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the clinical efficacy, safety and immunological changes of secukinumab(sec) compared to adalimumab(ada) in patients with active ankylosing spondylitis(AS), who previously have an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) or bioagents.
Timeline
- Start
- 2022-03-15
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |
| Subject | Secukinumab | Monoclonal antibody | 150 mg | — |
| Background | Thalidomide | Other / unclassified | 50 mg | — |